Last updated: August 27, 2024
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Squamous Cell Carcinoma
Head And Neck Cancer
Carcinoma
Treatment
Paclitaxel (neoadjuvant)
Anti-PD-1 Drugs
Carboplatin( neoadjuvant)
Clinical Study ID
NCT06575322
SYSKY-2024-646-01
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- 1: Clinical diagnosis of head and neck squamous cell carcinoma (stage I-IVA),without prior treatment, and planning to undergo either surgical treatment alone orsurgical treatment combined with chemotherapy and immunotherapy.
2: Ability to speak Chinese and possess basic reading and writing skills.
Exclusion
Exclusion Criteria:
- 1: Presence of mental illnesses such as dementia or delirium.
2: Active use of narcotic drugs, including consuming alcohol more than 4 times perday or more than 4 times per week.
3: Patients who alter their treatment plan during the course of treatment.
4: Current or prior use of antidepressants.
Study Design
Total Participants: 302
Treatment Group(s): 4
Primary Treatment: Paclitaxel (neoadjuvant)
Phase:
Study Start date:
September 01, 2024
Estimated Completion Date:
March 01, 2027
Connect with a study center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guanzhou, Guangdong 510000
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.